newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

Prioritizing Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 Dr. Anthony Quinn, President, CEO and Board Member, has Stepped Down from His Current Po